Peer Review | An Analysis of 20 Independently Performed Assays to Measure Homologous Recombination Deficiency (HRD) in Ovarian Cancer: Findings from the Friends’ HRD Harmonization Project
Public Comment | Cancer Clinical Trial Eligibility Criteria: Patients with HIV, Hepatitis B Virus, or Hepatitis C Virus Infections
Poster | 2022 AMP Annual Meeting | Assessing Variability Across HRD Assays: Findings from the Friends’ HRD Harmonization Project
Poster | 2023 AACR Annual Meeting | Findings from the Friends of Cancer Research HRD Harmonization Project
2023 Scientific Report
2022 Scientific Report
Peer Review | Homologous Recombination Deficiency: Concepts, Definitions, and Assays
Abstract Background Homologous recombination deficiency (HRD) is a phenotype that is characterized by the inability of a cell to effectively repair DNA double-strand breaks using the homologous recombination repair (HRR) pathway. Loss-of-function genes involved in this pathway can sensitize tumors to poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors and platinum-based chemotherapy, which target the destruction of…